A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis
NCT07801495
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this Phase 2a/b study is: to evaluate the efficacy, safety and tolerability of DDY391 in participants with psoriatic arthritis (PsA). to determine the dose-response relationship of DDY391 in participants with PsA to support dose selection for Phase 3.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Moderate to Severe Psoriatic Arthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Novartis Pharmaceuticals
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Tennessee · 1
- Shelby Research LLC · Memphis, TN
Texas · 2
- Precision Comprehensive Research · Colleyville, TX
- Rheumatology Associates of South Texas · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.